STRO insider transaction filings
SUTRO BIOPHARMA, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-09. Screen STRO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-09 | 4 | Hunter Heidi — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Dybbs Michael — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Wigginton Jon Marc — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Jagpal Sukhi — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Lobacki Joseph M — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Petree Daniel H — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | MATSUI CONNIE — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | PANEK JAMES P — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Chow Gregory K. — CFO | Option exercise (M): 2,500 @ $0 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Pauling David — Chief Admin. Ofcr. & GC | Option exercise (M): 675 @ $0 · Tax withholding (F): 277 @ $21.31 · Option exercise (M): 675 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Chung Jane — Chief Executive Officer, Director | Option exercise (M): 788 @ $0 · Tax withholding (F): 282 @ $21.31 · Option exercise (M): 788 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Pauling David — Chief Admin. Ofcr. & GC | Option exercise (M): 500 @ $0 · Option exercise (M): 842 @ $0 · Tax withholding (F): 551 @ $20.47 · Option exercise (M): 2,356 @ $0 · Tax withholding (F): 970 @ $20.55 · Option exercise (M): 500 (derivative) @ $0 · +4 more | EDGAR |
| 2026-03-03 | 4 | Gerber Hans-Peter — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 1,125 @ $0 · Tax withholding (F): 463 @ $20.47 · Option exercise (M): 2,843 @ $0 · Tax withholding (F): 1,170 @ $20.55 · Option exercise (M): 1,125 (derivative) @ $0 · Option exercise (M): 2,843 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-03 | 4 | Chung Jane — Chief Executive Officer, Director | Option exercise (M): 688 @ $0 · Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,271 @ $20.47 · Option exercise (M): 7,750 @ $0 · Tax withholding (F): 2,779 @ $20.55 · Option exercise (M): 688 (derivative) @ $0 · +4 more | EDGAR |
| 2026-03-03 | 4 | Chow Gregory K. — CFO | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Pauling David — Chief Admin. Ofcr. & GC | Grant/award (A): 7,200 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Gerber Hans-Peter — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 7,925 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Hunter Heidi — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Chow Gregory K. — CFO | Grant/award (A): 8,200 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Dybbs Michael — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Wigginton Jon Marc — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Jagpal Sukhi — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Lobacki Joseph M — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Petree Daniel H — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | MATSUI CONNIE — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | PANEK JAMES P — Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Chung Jane — Chief Executive Officer, Director | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 894 @ $8.02 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Pauling David — Chief Admin. Ofcr. & GC | Purchase (P): 12,504 @ $0.80 | EDGAR |
| 2025-10-16 | 4 | Gerber Hans-Peter — CHIEF SCIENTIFIC OFFICER | Purchase (P): 17,000 @ $0.80 | EDGAR |
| 2025-10-16 | 4 | Chung Jane — Chief Executive Officer, Director | Purchase (P): 12,500 @ $0.80 | EDGAR |
| 2025-10-16 | 4 | Chow Gregory K. — CFO | Purchase (P): 19,750 @ $0.81 | EDGAR |
| 2025-10-16 | 4 | MATSUI CONNIE — Director | Purchase (P): 50,000 @ $0.80 | EDGAR |
| 2025-09-22 | 4 | Gerber Hans-Peter — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 37,500 @ $0 · Tax withholding (F): 13,417 @ $0.90 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Leyman Barbara — Chief Business Officer | Option exercise (M): 25,000 @ $0 · Tax withholding (F): 8,944 @ $0.78 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Chung Jane — Chief Executive Officer, Director | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 6,708 @ $0.80 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Wigginton Jon Marc — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Lobacki Joseph M — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Jagpal Sukhi — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hunter Heidi — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Dybbs Michael — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Petree Daniel H — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | MATSUI CONNIE — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | PANEK JAMES P — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Chow Gregory K. — CFO | Grant/award (A): 275,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | ALBINI EDWARD C — CFO AND SECRETARY | Option exercise (M): 24,438 @ $0 · Option exercise (M): 11,156 @ $0 · Option exercise (M): 9,125 @ $0 · Tax withholding (F): 15,995 @ $0.88 · Option exercise (M): 24,438 (derivative) @ $0 · Option exercise (M): 11,156 (derivative) @ $0 · +1 more | EDGAR |
| 2025-05-05 | 4 | Srinivasan Venkatesh — CHIEF TECH OP OFFICER | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 894 @ $1.07 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Borgman Anne Elizabeth — CHIEF MEDICAL OFFICER | Option exercise (M): 53,125 @ $0 · Option exercise (M): 15,938 @ $0 · Tax withholding (F): 24,709 @ $1.07 · Option exercise (M): 53,125 (derivative) @ $0 · Option exercise (M): 15,938 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | FITZPATRICK LINDA A — CHIEF PEOPLE & COMM. OFFICER | Option exercise (M): 9,125 @ $0 · Option exercise (M): 9,740 @ $0 · Option exercise (M): 13,140 @ $0 · Option exercise (M): 5,844 @ $0 · Tax withholding (F): 13,538 @ $1.07 · Option exercise (M): 9,125 (derivative) @ $0 · +3 more | EDGAR |
| 2025-04-15 | 4 | Srinivasan Venkatesh — CHIEF TECH OP OFFICER | Option exercise (M): 21,250 @ $0 · Tax withholding (F): 7,603 @ $0.60 · Option exercise (M): 21,250 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | Chung Jane — Chief Executive Officer, Director | Grant/award (A): 620,000 (derivative) @ $0 · Grant/award (A): 310,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — SUTRO BIOPHARMA, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-03 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=STRO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →